Ascendis Pharma A/s

Ascendis Pharma Growth Disorders A/s

Sanofi-a Ventis Deutschland Gmbh

Ascendis Pharma Endocrinology Division A/s

Ascendis Pharma Inc.

Ascendis Pharma Growth Disorders Division A/s

Complex Biosystems Gmbh

Ulrich Hersel

Harald Rau

Thomas Wegge

Kennett Sprogøe

Felix Cleemann

Dirk Vetter

Robert Schnepf

Oliver Keil

Guillaume Maitro

Caroline Elisabeth Rasmussen

Grethe Norskov Rasmussen

Torben Lessmann

Joachim Zettler

Tobias Voigt

Susanne Kindermann

Silvia Kaden-Vagt

Kennett Sprogoe

Mathias Krusch

Nicola Bisek

Torben Lessman

Nora Kaluza

Torben Leßmann

Thomas Knappe

Grethe Nørskov Rasmussen

Burkhardt Laufer

Romy Reimann

Torben Lebmann

Anja R H Skands

Julia Baron

Felix Cleenmann

Ana Bernhard

Susanne Kinderman

Frank Faltinger

Silvia Kaden

Charlotte Pinholt

Stefan Heinig

Kennett SprogØe

Torben LEßMANN

A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety.

Dry pharmaceutical formulations of CNP conjugates

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.

PEGylated recombinant human growth hormone compounds

The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an ECthat is at least 20-fold higher than the ECof the corresponding free CNP agonist and which released CNP agonist has an ECthat is at most 3-fold higher than the ECof the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

Controlled-release CNP agonists with low initial NPR-B activity

The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.

CNP prodrugs with carrier attachment at the ring moiety

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

Controlled-release CNP agonists with increased NEP stability

The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

Biodegradable polyethylene glycol based water-insoluble hydrogels

The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.

Controlled-release CNP agonists with reduced side-effects

The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

Controlled-release CNP agonists with low NPR-C binding

The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety &#x2014;Z that is conjugated through a moiety -L- to a reversible prodrug linker moiety -L-, which reversible prodrug linker moiety -L- is covalently and reversibly conjugated to -D; wherein -L- is a chemical bond or a spacer; and &#x2014;Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.

CNP prodrugs with large carrier moieties

The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-biologically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament.

Hydrogel-linked prodrugs releasing tagged drugs

The present invention relates to a polymeric prodrug for use in the treatment, prevention and/or diagnosis a disease of the joint and pharmaceutical compositions and medical devices comprising said polymeric prodrugs.

Diagnosis, prevention and treatment of diseases of the joint

Growing community of inventors

Heidelberg, Germany

Ulrich Hersel